

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

UPDATE ON THE INVESTIGATION

Reference is made to the announcements of GenScript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 21 September 2020, 22 November 2020, 9 February 2021, and 25 May 2021 in relation to the investigation relating to suspected violations of import and export regulations under the laws of the People’s Republic of China by the Customs Anti-Smuggling Department of Zhenjiang in the People’s Republic of China (the “**PRC**”) (the “**Investigation**”) (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

This announcement is made by the board of directors (the “**Board**”) of the Company pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company has been informed that each of (i) Dr. Zhang Fangliang (章方良) (“**Dr. Zhang**”) (being the former director, chairman and chief executive officer of the Company and former director, chairman and chief executive officer of Legend Biotech Corporation), (ii) Nanjing GenScript Biotech Co., Ltd.* (南京金斯瑞生物科技有限公司) (being an indirect wholly-owned subsidiaries of the Company), (iii) Jiangsu GenScript Biotech Co., Ltd.* (江蘇金斯瑞生物科技有限公司) (being an indirect wholly-owned subsidiaries of the Company), and (iv) three current employees and one former employee of the Company who have been involved in certain import and export activities of the Group, has been notified by the Zhenjiang Municipal People’s Procuratorate (the “**Procuratorate**”) that the examination with respect to the Investigation has been concluded, and that the Procuratorate decided not to bring any charge against any entity or individual (the “**Decision**”). As advised by the PRC legal advisor of the Company, the Decision means that the prosecution procedure together with any underlying investigation have now been concluded, and that none of the Company, any of its subsidiaries, Dr. Zhang, or any of the abovementioned current and former employees has or will have any criminal liability with respect to the Investigation.

As at the date of this announcement, the Group’s business operations and financial conditions remain normal.

The Company will make further announcement in a timely manner on any important development of the matter.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
GenScript Biotech Corporation
Meng Jiange
Chairman and Executive Director

Hong Kong, 2 May 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* *For identification purposes only*